The stock of Akoya Biosciences Inc (AKYA) has seen a 8.42% increase in the past week, with a -3.74% drop in the past month, and a 57.65% flourish in the past quarter. The volatility ratio for the week is 9.48%, and the volatility levels for the past 30 days are at 6.77% for AKYA. The simple moving average for the past 20 days is 4.88% for AKYA’s stock, with a -9.37% simple moving average for the past 200 days.
Is It Worth Investing in Akoya Biosciences Inc (NASDAQ: AKYA) Right Now?
Additionally, the 36-month beta value for AKYA is 1.35. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AKYA is 22.11M and currently, short sellers hold a 9.14% ratio of that float. The average trading volume of AKYA on November 06, 2024 was 144.81K shares.
AKYA) stock’s latest price update
Akoya Biosciences Inc (NASDAQ: AKYA) has experienced a rise in its stock price by 17.94 compared to its previous closing price of 2.62. However, the company has seen a gain of 8.42% in its stock price over the last five trading days. globenewswire.com reported 2024-10-28 that MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
AKYA Trading at 10.16% from the 50-Day Moving Average
After a stumble in the market that brought AKYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.03% of loss for the given period.
Volatility was left at 6.77%, however, over the last 30 days, the volatility rate increased by 9.48%, as shares sank -0.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.10% upper at present.
During the last 5 trading sessions, AKYA rose by +8.42%, which changed the moving average for the period of 200-days by -38.93% in comparison to the 20-day moving average, which settled at $2.95. In addition, Akoya Biosciences Inc saw -36.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKYA starting from McKelligon Brian, who sale 7,500 shares at the price of $2.08 back on Jun 11 ’24. After this action, McKelligon Brian now owns 224,733 shares of Akoya Biosciences Inc, valued at $15,630 using the latest closing price.
McKelligon Brian, the President and CEO of Akoya Biosciences Inc, sale 7,500 shares at $2.01 during a trade that took place back on Jun 06 ’24, which means that McKelligon Brian is holding 224,733 shares at $15,064 based on the most recent closing price.
Stock Fundamentals for AKYA
Current profitability levels for the company are sitting at:
- -0.52 for the present operating margin
- 0.56 for the gross margin
The net margin for Akoya Biosciences Inc stands at -0.65. The total capital return value is set at -0.44. Equity return is now at value -128.20, with -36.29 for asset returns.
Based on Akoya Biosciences Inc (AKYA), the company’s capital structure generated 0.78 points at debt to capital in total, while cash flow to debt ratio is standing at -0.65. The debt to equity ratio resting at 3.55. The interest coverage ratio of the stock is -9.18.
Currently, EBITDA for the company is -47.14 million with net debt to EBITDA at -1.74. When we switch over and look at the enterprise to sales, we see a ratio of 2.45. The receivables turnover for the company is 5.63for trailing twelve months and the total asset turnover is 0.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.73.
Conclusion
In conclusion, Akoya Biosciences Inc (AKYA) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
